Optimizing Adjuvant EGFR-Targeted Therapy in Early-Stage EGFR-Mutated NSCLCs

Experts explain how adjuvant osimertinib changes post-surgery EGFR lung cancer care, from rapid testing to real-world adherence.

NEADORA data highlights why early NGS guides resectable EGFR lung cancer care, favoring perioperative osimertinib and avoiding checkpoint inhibitors.